Pyxis Oncology, Inc. (PYXS)
2.69
-0.38
(-12.38%)
USD |
NASDAQ |
Jul 08, 16:00
2.68
-0.01
(-0.37%)
After-Hours: 20:00
Pyxis Oncology Price to Book Value : 5.405 for July 8, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| July 08, 2026 | 5.405 |
| July 07, 2026 | 6.169 |
| July 06, 2026 | 4.943 |
| July 02, 2026 | 5.285 |
| July 01, 2026 | 5.727 |
| June 30, 2026 | 6.048 |
| June 29, 2026 | 5.747 |
| June 26, 2026 | 5.566 |
| June 25, 2026 | 4.481 |
| June 24, 2026 | 4.360 |
| June 23, 2026 | 4.220 |
| June 22, 2026 | 4.280 |
| June 18, 2026 | 4.079 |
| June 17, 2026 | 3.818 |
| June 16, 2026 | 3.516 |
| June 15, 2026 | 3.496 |
| June 12, 2026 | 3.537 |
| June 11, 2026 | 3.356 |
| June 10, 2026 | 3.356 |
| June 09, 2026 | 3.416 |
| June 08, 2026 | 3.396 |
| June 05, 2026 | 3.577 |
| June 04, 2026 | 3.436 |
| June 03, 2026 | 3.416 |
| June 02, 2026 | 3.436 |
| Date | Value |
|---|---|
| June 01, 2026 | 3.597 |
| May 29, 2026 | 3.617 |
| May 28, 2026 | 3.577 |
| May 27, 2026 | 3.476 |
| May 26, 2026 | 3.275 |
| May 22, 2026 | 3.938 |
| May 21, 2026 | 3.898 |
| May 20, 2026 | 4.019 |
| May 19, 2026 | 3.838 |
| May 18, 2026 | 4.059 |
| May 15, 2026 | 4.582 |
| May 14, 2026 | 4.441 |
| May 13, 2026 | 5.265 |
| May 12, 2026 | 5.224 |
| May 11, 2026 | 5.526 |
| May 08, 2026 | 5.506 |
| May 07, 2026 | 4.541 |
| May 06, 2026 | 4.622 |
| May 05, 2026 | 3.677 |
| May 04, 2026 | 3.537 |
| May 01, 2026 | 3.456 |
| April 30, 2026 | 3.416 |
| April 29, 2026 | 3.336 |
| April 28, 2026 | 3.416 |
| April 27, 2026 | 3.537 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| NanoViricides, Inc. | 3.666 |
| ACADIA Pharmaceuticals, Inc. | 3.564 |
| Alnylam Pharmaceuticals, Inc. | 40.14 |
| Anika Therapeutics, Inc. | 1.63 |
| Savara, Inc. | 7.427 |
Price to Book Value Related Metrics
| PS Ratio | 12.16 |
| Price | 2.69 |
| Earnings Yield | -48.46% |
| Market Cap | 169.02M |